ESMO-RUSSCO SUMMIT (10-11 JUNE 2019, Kazan, RUSSIAN FEDERATION)

ESMO-RUSSCO SUMMIT

Kazan
RUSSIAN FEDERATION
10-11 JUNE 2019


Venue: Kazan, st. Peterburgskaya, 1, Grand Hotel Kazan.




Co-chairs
Andrés Cervantes, Spain
Alexey Tryakin, Russia

Faculty

Mona Frolova, Russian Federation
Giuseppe Curigliano, Italy
Andrés Cervantes, Spain
Rolf A. Stahel, Switzerland
Christos Sotiriou, Belgium
Domenica Lorusso, Italy

Sergei Tjulandin, Russian Federation
Fedor Moiseenko, Russian Federation
Alexey Smolin, Russian Federation
Ilya Pokataev, Russian Federation
Alexandra Tyulyandina, Russian Federation
Alexey Tryakin, Russian Federation


Learning Objectives

  • To provide the oncology community with a summary of the most significant treatment advances presented at the ESMO Congresses
  • To review the current standard of care for key malignancies from a local and international perspective
  • To discuss the current controversies in the management of specific cancers

Accreditation
The programme of this event has been accredited with 13 ESMO-MORA Category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.


PROGRAMME

Monday, 10th June 2019

Hall «Gabdulla Tukay»

08:00 – Registration


Welcome & Introduction

08:20-08:30 – Welcome Address
Andre's Cervantes, Spain, and Alexey Tryakin, Russia

08:30-08:40 – Welcome from the chief oncologists of the Russian Federation
Ivan Stilidi, Russia, and Andrey Kaprin, Russia

08:40-08:50 – Welcome from the local Committee (Republic of Tatarstan)
Marat Sadykov, Russia, and Rustem Khasanov, Russia

08:50-08:55 – Introduction by ESMO Educational Committee Chair
Andre's Cervantes, Spain

08:50-09:00 – Introduction by RUSSCO Сhair
Sergei Tjulandin, Russia


SESSION 1. Breast Cancer

Chair:
Giuseppe Curigliano, Italy
Mona Frolova, Russia

09:00-09:30 – Current standards and practice changing studies in Early Breast Carcinoma
Giuseppe Curigliano, Italy

09:30-10:00 – Current standards and practice changing studies in Advanced HER2-positive and Triple Negative Breast carcinoma
Christos Sotiriou, Belgium

10:00-10:30 – Current standards and practice changing studies in Advanced HR-positive Breast Cancer
Mona Frolova, Russia

10:30-10:40 – Q&A

10:40-11:00 – Coffee break

11:00-12:00 – Clinical cases presentation
Elena Glazkova, Russia
Ramazan Iskenderov, Russia
Alfiya Khasanova, Russia

12:00-12:15 – Panel discussion


Hall «Gabdulla Tukay»
12:30-13:30 – AstraZeneka satellite symposia

AstraZeneka

AstraZeneka symposium

12:30-12:35 – Opening remarks
Sergei Tjulandin, Russia

12:35-12:55 – Newly identified BRCA-associated ovarian cancer – is it possible not to wait for a relapse?
Svetlana Khokhlova, Russia

12:55-13:10 – Recurrence of ovarian cancer beyond the BRCA mutations
Alexandra Tyulyandina, Russia

13:10-13:25 – BRCA-associated breast cancer
Ludmila Zhukova, Russia

13:25-13:30 – Discussion. Closing remarks
Sergei Tjulandin, Russia


* Not covered by NMO

13:30-13:45 – Coffee break


SESSION 2. Gynaecological Cancer

Chair:
Domenica Lorusso, Italy
Alexandra Tyulyandina, Russia

13:45-14:15 – Current standards and practice changing studies in Ovarian Carcinoma
Alexandra Tyulyandina, Russia

14:15-14:45 – Current standards and practice changing studies in Endometrial Carcinoma
Domenica Lorusso, Italy

14:45-15:15 – Current standards and practice changing studies in Cervical Carcinoma
Domenica Lorusso, Italy

15:15-15:25 – Q&A

15:25-15:45 – Coffee break

15:45-16:45 – Clinical cases presentation
Aleksey Rumyantsev, Russia
Dmitriy Utkin, Russia
Gulnara Mukhamediarova, Russia

16:45-17:00 – Panel discussion


Hall «Gabdulla Tukay»
17:15-18:15 – Bayer satellite symposia

Bayer

Bayer satellite symposia

New opportunities for target therapy of patients with GI tumors

Chairman:
Valery Breder, Russia

17:15-17:20 – Introduction by Chairman

17:20-17:45 – HCC treatment paradigm: looking for optimal decisions
Valery Breder, Russia

17:45-18:10 – Therapy algorithm for pre-treated patients with mCRC
Mikhail Fedyanin, Russia

18:10-18:15 – Q&A section
Valery Breder, Russia


* Not covered by NMO

Hall «Salikh Saydashev»
17:15-18:15 – Pfizer satellite symposia

Pfizer

Pfizer satellite symposia

Practical Aspects of Luminal HER2-negative Metastatic Breast Cancer Treatment:
The Search for Optimal Solutions

Chairman:
Ludmila Zhukova, Russia

17:15-17:35 – CDK 4/6 inhibitors contribution to achieving HR+ HER2– mBC treatment goals
Marina Stenina, Russia

17:35-17:50 – Tolerability of combined therapy with CDK 4/6 inhibitors and monitoring aspects
Ludmila Zhukova, Russia

17:50-18:10 – Case study: treatment decision making and management in patients with HR+ HER2- mBC
Irina Koroleva, Russia

18:10-18:15 – Questions and answers


* Not covered by NMO


Tuesday, 11th June 2019

Hall «Gabdulla Tukay»

SESSION 3. Lung Cancer

Chair:
Rolf A. Stahel, Switzerland
Fedor Moiseenko, Russia

09:00-09:20 – Current standards and practice changing studies in NSCLC stage I-III
Rolf A. Stahel, Switzerland

09:20-09:50 – Current standards and practice changing studies in metastatic NSCLC without actionable mutations
Fedor Moiseenko, Russia

09:50-10:20 – Current standards and practice changing studies in metastatic NSCLC with actionable mutations
Rolf A. Stahel, Switzerland

10:20-10:35 – Coffee break

10:35-10:55 – Current standards and practice changing studies in SCLC
Alexey Smolin, Russia

10:55-11:10 – Q&A

11:10-12:10 – Clinical cases presentation
Elizaveta Artem'yeva, Russia
Rafael Enickeev, Russia

12:10-12:25 – Panel discussion


Hall «Gabdulla Tukay»
12:40-13:40 – AstraZeneka satellite symposia

AstraZeneka

AstraZeneka symposium

Start of the new opportunities in stage III NSCLC treatment

Moderator:
Konstantin Laktionov, Russia

12:40-12:45 – Introduction
Konstantin Laktionov, Russia

12:45-13:00 – Unresectable stage III of NSCLC. How can we achieve the maximum efficacy of CRT?
Natalia Dengina, Russia

13:00-13:20 – Innovative approaches in treatment of patients with unresectable stage III of NSCLC
Konstantin Laktionov, Russia

13:20-13:35 – Immunotherapy implementation in combination with CRT in stage III NSCLC in clinical practices
Olga Goncharova, Russia

13:35-13:40 – Q&A session
Konstantin Laktionov, Russia


* Not covered by NMO

Hall «Salikh Saydashev»
12:40-13:40 – MSD satellite symposia

MSD

MSD satellite symposia

How to select the "right" patient for Immunotherapy?

Chairman:
O.A. Gladkov, Russia

Immunotherapy for NSCLC treatment: what else to consider except for PD-L1 expression?
F.V. Moiseenko, Russia

Immunotherapy for MSI-H tumors: when to test for MSI-H?
O.A. Gladkov, Russia


* Not covered by NMO

Hall «Adel' Kutuy»
12:40-13:40 – BMS satellite symposia

BMS

BMS symposium

Chairman:
Alexey Tryakin, Russia

Nivolumal as a backbone for combination immunotherapy in solid tumors:

12:40-12:55 – In metastatic melanoma
Galina Kharkevich, Russia

12:55-13:10 – In lung cancer
Alexey Smolin, Russia

13:10-13:25 – In oncourology
Maria Volkova, Russia

13:25-13:40 – In GI tumors
Alexey Tryakin, Russia


* Not covered by NMO

13:40-14:00 – Coffee break


SESSION 4. GI Cancers

Chair:
Andrés Cervantes, Spain
Ilya Pokataev, Russia

14:00-14:30 – Current standards and practice changing studies in Pancreatic and Hepatic Carcinoma
Ilya Pokataev, Russia

14:30-15:00 – Current standards and practice changing studies in Esophageal and Gastric Carcinoma
Alexey Tryakin, Russia

15:00-15:30 – Current standards and practice changing studies in Advanced Colon Carcinoma
Andrés Cervantes, Spain

15:30-15:40 – Q&A

15:40-16:00 – Coffee break

16:00-16:20 – Current standards and practice changing studies in Localized Rectal Cancer
Andrés Cervantes, Spain

16:20-17:20 – Clinical cases presentation
Elizaveta Polyanskaya, Russia
Anna Popova, Russia
Sergey Belukhin, Russia

17:20-17:40 – Panel discussion


17:40-18:00 – Adjourn and Close Remarks